Background {#Sec1}
==========

Today, the integration and compilation of the large volume of data generated from clinical studies is challenging. This data has to be available to be used in companion diagnostic and prognostic tests which in turn are crucial at every level of clinical decision making. A multi-fold of patient samples is stored in biobanks for use in future medical research projects that measure the quantitative and qualitative read-outs of gene and protein expression associated with disease processes (1--2). Furthermore, biobanking laws that regulate data processing, integration, traceability, and confidentiality are implemented on a national level.

In Sweden, all institutions storing biological samples and clinical data are required to declare their inventories to the National Board of Health and Welfare. Sweden had 651 biobanks registered with the Board in 2007, the majority deployed at University hospitals and Regional Medical Authorities. The samples come from many forms of specimen including tissues, cells, cell lines, genomic material (DNA), blood, blood-plasma, and urine.

Project organization is essential to face the challenges in clinical studies, i.e., patient recruitment, appointment scheduling, blood samples collection etc. Additionally, other parts of the study are also important, such as sample storage, analysis, evaluation of the results, and compilation of data into a useful database. The latter part of the study may continue for a long time after clinical data collection is completed which is why a high quality database is crucial.

REDCap is a web-based EDC (Electronic Data Capture) tool developed by Vanderbilt University, TN, USA first released in 2004 \[[@CR1]\]. REDCap is a secure application designed to support data capture in research studies with a user-friendly interface for data entry, audit trial to track data manipulation and export procedures, import data from external sources, and export procedures for data download to common statistical packages. We selected REDCap as the EDC tool for the current clinical study due to a version controlled update of the software, a massive user support, easy export/import of data using CSV-files (Comma-Separated Values), a large community of users, and the possibility to easily design different data collection instruments for various types of data input, e.g., text and numerical values.

KOL-Örestad is a 5-year longitudinal clinical study created to identify new biomarkers of COPD (Chronic Obstructive Pulmonary Disease) in blood. The biomarkers can be used to *diagnose* the disease, *predict* exacerbations, and to *classify* disease stages of COPD \[[@CR2]\]. An early diagnosis would be beneficial to the patient, health-care system, and society due to lower medical costs and reduced sick leave. In the present study we describe how to transfer clinical chemistry data from the hospital information system to the KOL-Örestad database with a simple and secure EDC solution. Throughout the course of the study, blood samples are drawn from the participants at a private health-care clinic (Örestadskliniken), encoded, and sent to a public clinical chemistry laboratory. The analysis of these samples results in large number of numerical data values that need to be imported into the REDCap database. To enter that amount of data manually is time-consuming and error-prone. Instead, taking an approach that is automatic and indifferent to variable identifiers and order of variables is preferred.

In proteomic research it is critical that sample quality is preserved during storage, that sample inventories are maintained, and that the data produced by mass spectrometry or similar techniques is readily available for statistical analysis. This puts requirements on both the biobanks the samples are stored in as well as on inventory software and EDC tools.

Methods {#Sec2}
=======

Clinical study outline {#Sec3}
----------------------

The study group consists of approximately 300 study participants between the ages of 35 and 80 years. Two-hundred are diagnosed with COPD of one of the four stages of GOLD and 100 are healthy with normal lung function, both smokers/ex-smokers (*n* = 50) and never-smokers (*n* = 50). Participants undergo health examinations and blood sample collection every 6 months for a total of 5 years. Health examination includes a spirometer test, physical examination, and questionnaire \[[@CR2]\]. Because the old classification system was in use at the initiation of the study, we will continue to use GOLD 1 to 4 based solely on post bronchodilator spirometry values.

Three 5 mL tubes of blood are sampled and analyzed for a set of predetermined disease biomarkers at a standard clinical chemistry laboratory and four tubes are aliquoted to 70 μL samples (plasma, serum, & whole blood) and stored in a biobank at -80^o^ C for protein biomarker analysis by mass spectrometry \[[@CR3]--[@CR8]\]. Each aliquot has a unique 2D barcode which may be traced back to the participant. The study has been approved by the regional ethical review board in Lund (DRN 2013/480) and is registered at ClinicalTrials.gov under the official title Biomarkers of Early Chronic Obstructive Pulmonary Disease (COPD) in Smokers - Longitudinal Study (U.S. National Institutes of Health, 2014).

Data sources {#Sec4}
------------

The study consists of different data input sources where each source has multiple variables of data that are to be stored in the same database. One data source is the primary health-care clinic where all visits are made. At each visit, the study participants fill out a questionnaire by hand and the responses are entered manually into REDCap by members of the research team. Additionally, the results from the physical examination and spirometry test are also entered manually into REDCap. The tubes from blood collection are labeled with barcodes identifying the study participant with a specific code and are entered into REDCap by a barcode scanner. The data is coded by a unique identifier (Study ID) for each participant and the full identification is solely available to the health-care personnel. However, full traceability from sample to Study ID will be accessible within the system.

Database structure {#Sec5}
------------------

The data is entered into REDCap at different locations and time points. Some data is entered manually and some is entered using the import function of REDCap. Preferably, all data should be entered automatically or electronically, e.g., through an automated direct input, digital scanning of the paper format, or import file from a data generating source. Currently, this is not possible in the present study; however, this is our goal.

Data import to REDCap {#Sec6}
---------------------

The web interface of REDCap provides an import module that screens the data for errors before committing it to the database; e.g., errors such as incorrectly formatted data values or numerical values that lie beyond pre-defined bounds can be caught at this stage. Both batches of data as well as single data values can be imported through this module. Data batches are imported from CSV files whose format is required to match that which REDCap expects. Consequently, when an instrument generates a CSV files containing biomarker data it has to be translated, either manually or automatically, to this expected format. In addition to the import functions of the web user-interface, REDCap provides a web API that allows users to programmatically import and retrieve data to and from REDCap through HTTP methods. Lastly, the back-end of REDCap, a MySQL database, can be directly modified; however, this bypasses the above mentioned data screening \[[@CR1]\].

Results {#Sec7}
=======

The study participants have their blood drawn, fill out questionnaires, and undergo physical examinations at the private health-care clinic. Members of the research team enter data from questionnaires and physical examinations manually into REDCap. The blood samples from each participant are sent both to BMC to be stored in a biobank and to a clinical chemistry facility in Malmö for disease biomarker analysis. The data generated by the biomarker analysis is stored in REDCap. Mass spectrometry (MS) analysis is performed on the biobank samples and the produced data is stored in a separate, dedicated, database. Results from analysis of the raw MS data, e.g., PSMs (Peptide-to-Spectrum Matches) or FDRs (False Discovery Rates), as well as data related to the experimental setup can also be stored in REDCap. The flow of samples and data can be viewed in Fig. [1](#Fig1){ref-type="fig"}. The data collected within the study, the data formats, and the input methods can be viewed in Table [1](#Tab1){ref-type="table"}.Fig. 1The sample and data flow of the study. Blood samples are drawn, physical examinations are performed, and health questionnaires are filled out at the health-care center. Blood samples are sent to the Clinical Chemistry center for analysis. Blood samples are also aliquoted and analyzed for protein biomarkers by SRM LC-MS/MS at the research center. The patient identifying data is stored in the same database as the rest of the data but is solely accessible to personnel at the health-care clinic Table 1Current data collection instruments, data format and input method to the KOL-Örestad database.SourceFormatInput methodBlood samplesnumber, text, date, check boxmanual, barcode scannerPhysical examinationnumerical valuemanual input from patient journalSpirometrynumbermanual input from paperQuestionnairenumber, text, check boxmanual input from paperCC analysisnumberimport from data fileMS analysisnumber, textimport from data fileThe qualitative and quantitative output of the MS analysis (as well as its corresponding meta-data, e.g., MS platform, instrument setttings, Sequence Database, etc.) is stored in REDCap whereas instrument raw files are stored in a separate database

At the start of the study all data was imported manually into REDCap through its web interface. We chose to focus on automating the clinical chemistry data (CC data) importation since it involves the largest volume of data. The clinical chemistry laboratory instruments used to perform the biomarker analysis in the study automatically generate CSV files containing CC data. These files are formatted differently than those exported from and imported to REDCap. The instrument-generated files represent the data according to the EAV(Entity-Attribute-Value) model whereas the REDCap files mirror the flat table representation of the *DATA* table of the REDCap MySQL back-end. Furthermore, if the attribute and entity identifiers differ between the instrument and REDCap files the instrument files are not accepted by the batch import function of REDCap \[[@CR1]\]. We created a program, DART (Data Rapid Translation), that automates the translation between the two formats. It extracts the biomarker data from the instrument-generated CSV file, re-formats it, and inserts it into the CSV file exported from REDCap. It does this by first translating the instrument-generated file to an intermediate hierarchical format which subsequently is translated to the format REDCap expects. DART is not exclusive to our particular pair of CSV files but can be configured to work with others as well.

DART was created using the C++ programming language. A minimal Graphical User Interface (GUI) was created using the wxWidgets library that allows the users to configure DART for different export/import formats, i.e., what the hierarchical structures look like and the mapping of the variable identifiers. DART is currently used in the study.

An example of biomarker data and how it can be represented in a CSV file is shown in Table [2](#Tab2){ref-type="table"}. The corresponding REDCap CSV file is shown in Table [3](#Tab3){ref-type="table"}. The list of disease biomarkers used in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} is truncated. At the five levels of the hierarchy of the example data are, from top to bottom; the study id, the study participants, the visits as well as exacerbations of the participants, the biomarkers, and the numerical data value belonging to each biomarker. The hierarchy of the example biomarker data is illustrated in Fig. [2](#Fig2){ref-type="fig"}. The variables are not required to have the same identifiers in the REDCap and biomarker CSV files. The hierarchy is inherently the same in the file exported from REDCap, only formatted differently. Granted that the hierarchy of the data, the relationship between the format of the biomarker file and that of the file exported from REDCap, and the mapping of variable identifiers are specified, DART can transfer the data.Table 2Example of laboratory instrument output, the data is modeled as EAVpat_idvisit_idexacerbation_idDateAttributeValue100001visit_1150321calcium6.2100001visit_1150321leukocytes6.5100002visit_1150321calcium2.45100002visit_1150321leukocytes6.5100001visit_2150917calcium2.51100001visit_2150917leukocytes6.2100002exacerbation_1150613calcium2.44100002exacerbation_1150613leukocytes8.1 Table 3Example of a flat table exported from the REDCap database with biomarker data yet to be enteredpatient_idredcap_event_nameNcaleucohbmono100001visit_1100002visit_1100001visit_2100002exacerbation_1 Fig. 2The hierarchy of the example data

Discussion {#Sec8}
==========

In Sweden, there is no standardized way to manage and transfer clinical data. This makes it desirable to use an already adopted and well tested tool. The decision to use REDCap as the primary data management tool in this study was motivated by its accessibility, due to a simple web interface, to a broad user spectrum. It is used globally, particularly by non-profit research organization, in clinical studies \[[@CR9]\]. The chosen approach where the database is exported as a CSV file, modified, and then imported back again, does not interfere with the built-in quality-control of data that REDCap provides. The alternative approach where the underlying database of REDCap is directly modified, while more straight-forward, circumvents this quality-control, and is thus more unsafe with respect to data integrity.

The combination of REDCap and DART is a flexible tool for the management of clinical study data. Some initial work has to be done when configuring the program for a particular import/export pair. Currently DART is solely used to import data into REDCap, it could, however, in a future iteration, also perform other tasks such as data analysis and/or presentation of data.

Conclusion {#Sec9}
==========

It is crucial to store both data from sample analyses as well as the biological samples themselves in an organized and secure way during clinical studies. Furthermore, the data and samples have to be readily accessible to researchers and health-care personnel. In the KOL-Örestad study we achieve this by using REDCap to manage and store the data and our biobank to store the samples and their aliquots.
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